Business Description
Inhibrx Biosciences Inc
NAICS : 541714
SIC : 2834
Description
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what they believe to be the most appropriate agonist function.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -0.38 | |||||
Debt-to-Equity | -0.25 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.17 | |||||
9-Day RSI | 42.32 | |||||
14-Day RSI | 48.72 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.37 | |||||
Quick Ratio | 0.37 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -2535.68 | |||||
ROA % | -181.75 | |||||
ROIC % | -250.07 | |||||
ROC (Joel Greenblatt) % | -516.17 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 122.95 | |||||
EV-to-EBIT | -4.19 | |||||
EV-to-EBITDA | -4.22 | |||||
EV-to-Revenue | 126.2 | |||||
EV-to-FCF | -4.98 | |||||
Earnings Yield (Greenblatt) % | -23.87 | |||||
FCF Yield % | -20.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INBX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibrx Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1.634 | ||
EPS (TTM) ($) | -3.46 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 48.72 | ||
14-Day ATR ($) | 1.122938 | ||
20-Day SMA ($) | 15.8495 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 12.95 - 18.95 | ||
Shares Outstanding (Mil) | 14.48 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Inhibrx Biosciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Inhibrx Biosciences Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Inhibrx Biosciences Inc Frequently Asked Questions
What is Inhibrx Biosciences Inc(INBX)'s stock price today?
The current price of INBX is $14.17. The 52 week high of INBX is $18.95 and 52 week low is $12.95.
When is next earnings date of Inhibrx Biosciences Inc(INBX)?
The next earnings date of Inhibrx Biosciences Inc(INBX) is 2024-08-30 Est..
Does Inhibrx Biosciences Inc(INBX) pay dividends? If so, how much?
Inhibrx Biosciences Inc(INBX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |